Trend Results : The Cancer


Blog Post Results (1-20 of 10000+)

FILTER RESULTS

A New Cancer Study Makes a Stronger Case Against Regular Soda Consumption

A new study is providing further evidence about the potentially life-threatening danger of drinking soda on a daily basis. Researchers from the University of Melbourne and Cancer Council Victoria found that people who regularly drink...Show More Summary

March for Melanoma – Walk to raise funds for life-changing research

5 minutes agoAustralia / Canberra : RiotACT

‘Australia’s national cancer’ – as melanoma is commonly called – is the most common cancer in young Australians aged between 15– 39-year-olds, making up 20 per cent of all cancer cases. According to the Melanoma Institute Australia, the cancer kills more young Australians aged 20 – 39 than any other cancer. Being the third most common […]

Homeopathy Explained

“Faith can move mountains, but sugar water can’t cure cancer.” Kurzgesagt explains the basics and origins of homeopathy. It’s often touted as an alternative to expensive treatments, even though it often does nothing except make you think it’s doing something.

Research to uncover factors behind bladder cancer progression receives ACS grant

(Penn State) To find new therapies for aggressive bladder cancer, researchers must first uncover what drives each subtype at the molecular level. That's why the American Cancer Society has awarded a grant to study bladder cancer development...Show More Summary

Scientists isolate cancer stem cells using novel method

Researchers at The University of Texas at Dallas have devised a new technique to isolate aggressive cells thought to form the root of many hard-to-treat metastasized cancers—a significant step toward developing new drugs that might target these cells.

UT Dallas scientists isolate cancer stem cells using novel method

(University of Texas at Dallas) Researchers at The University of Texas at Dallas have devised a new technique to isolate aggressive cells thought to form the root of many hard-to-treat metastasized cancers -- a significant step toward developing new drugs that might target these cells.

A physician sees end-of-life care through a religious lens

In my second year of residency, I was on the hematology/oncology service where we were taking care of a pleasant lady in her 80s who was admitted with pancreatic cancer. It was apparent that the disease had spread rapidly, and when we discussed her at rounds, we knew that she likely had a few months […]

New immune system regulator discovered

Researchers in Finland have discovered a new regulator of the immune system, a key factor that controls development of regulatory T cells. The discovery provides basis for new strategies for the treatment of both cancer and immune-mediated diseases.

FDA approves a 'historic' new type of leukemia treatment

The FDA approved a "historic" new cancer treatment for kids with leukemia, but it carries a big price tag.

Stiffness matters

(University of Freiburg) Nanomedicine entry into cancer cells can be tuned by modulating the stiffness of the plasma membrane.

Putting black skin cancer to sleep -- for good

(Max Delbrück Center for Molecular Medicine in the Helmholtz Association) An international research team has succeeded in stopping the growth of malignant melanoma by reactivating a protective mechanism that prevents tumor cells from dividing. Show More Summary

New strategy to target transcription factor STAT5 to combat leukaemia

(University of Veterinary Medicine -- Vienna) Acute myeloid leukaemia is the most common type of acute cancer of the blood and bone marrow in adults. AML progresses quickly and only 26 percent of the patients survive longer than 5 years as resistance against established treatments arises. Show More Summary

Phase I clinical trial shows some promise for investigational drug for melanoma

(UNC Lineberger Comprehensive Cancer Center) In JCI Insight, UNC Lineberger's Stergios Moschos, MD, and colleagues published the results of a phase I, multi-institution clinical trial for an investigational treatment for melanoma and other cancers with mutations in the BRAF or RAS genes.

MD Anderson receives $22 million in CPRIT funding for research, prevention and recruitment

(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center was awarded $22.3 million from the Cancer Prevention and Research Institute of Texas (CPRIT), accounting for 30 percent of the $73.5 million in awards CPRIT announced today.

Unexpected Reason Boobies Rock! Cancer Scammer Is Going Back to Jail

Reading from the Voice Media empire:Back in 2013, we told you about Boobies Rock!, which sent hot girls into bars to sell merchandise emblazoned with the company’s name that supposedly raised money to fight cancer — although many, if not most, of the proceeds allegedly went into the pocket of the organization’s founder, Adam Shryock. Over the [...]Show More Summary

Sangamo in $3 billion gene-editing deal with Gilead

9 hours agoHealth : Reuters: Health

(Reuters) - U.S. drugmaker Gilead Sciences Inc will use Sangamo Therapeutics Inc's gene-editing technology to develop cancer treatments in a deal potentially worth about $3 billion to Sangamo, the companies said on Thursday.

New method uses light and gold nanoparticles for highly targeted, non-invasive drug delivery

Over the last century, there has been astounding progress in medical science, leading to the development of efficient, effective medications for treating cancer and a wide variety of other diseases. But the random dispersion of drugs throughout the body often lowers their effectiveness and, even worse, damages healthy tissue. Show More Summary

Sadness: Polish violinist dies of breast cancer, at 36

10 hours agoMusic / Classical : Slipped Disc

The death has been announced of Anna Karkowska, one of two musician sisters who created a stir with a series of videos made with the London Symphony Orchestra. Anna died on February 14 of breast cancer in New York state, where she had made her home for the past 20 years.  

Gilead signs $3 billion licensing deal for Sangamo's gene-editing platform

10 hours agoHealth : Reuters: Health

(Reuters) - Gilead Sciences Inc will use Sangamo Therapeutics Inc's gene-editing technology platform to develop cancer treatments, in a collaboration deal worth more than $3 billion, the two companies said on Thursday.

Medical News Today: This specialized gel could improve cancer therapy

Researchers are testing a promising new gel-like medium capable of delivering a combination of therapeutic agents directly to the sites of primary tumors.

Copyright © 2015 Regator, LLC